Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.

European Journal of Medicinal Chemistry
Petra BřehováZlatko Janeba

Abstract

A series of novel acyclic nucleoside phosphonates (ANPs) was synthesized as potential adenylate cyclase inhibitors, where the adenine nucleobase of adefovir (PMEA) was replaced with a 5-substituted 2-aminothiazole moiety. The design was based on the structure of MB05032, a potent and selective inhibitor of fructose 1,6-bisphosphatase and a good mimic of adenosine monophosphate (AMP). From the series of eighteen novel ANPs, which were prepared as phosphoroamidate prodrugs, fourteen compounds were potent (single digit micromolar or submicromolar) inhibitors of Bordetella pertussis adenylate cyclase toxin (ACT), mostly without observed cytotoxicity in J774A.1 macrophage cells. Selected phosphono diphosphates (nucleoside triphosphate analogues) were potent inhibitors of ACT (IC50 as low as 37 nM) and B. anthracis edema factor (IC50 as low as 235 nM) in enzymatic assays. Furthermore, several ANPs were found to be selective mammalian AC1 inhibitors in HEK293 cell-based assays (although with some associated cytotoxicity) and one compound exhibited selective inhibition of mammalian AC2 (only 12% of remaining adenylate cyclase activity) but no observed cytotoxicity. The mammalian AC1 inhibitors may represent potential leads in developme...Continue Reading

References

Oct 2, 1986·Nature·E De ClercqP C Maudgal
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·R K SunaharaA G Gilman
Apr 28, 1999·Trends in Microbiology·D Ladant, A Ullmann
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·J Hanoune, N Defer
Feb 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yuequan ShenWei-Jen Tang
Oct 20, 2004·Critical Reviews in Microbiology·Nidhi AhujaRakesh Bhatnagar
May 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Mark D ErionWilliam N Lipscomb
Jun 21, 2006·Cellular and Molecular Life Sciences : CMLS·J U Linder
Jun 30, 2009·Molecular Aspects of Medicine·Wei-Jen Tang, Qing Guo
Nov 5, 2010·Dalton Transactions : an International Journal of Inorganic Chemistry·Elena SperottoJohannes G de Vries
Nov 2, 2011·Journal of Medicinal Chemistry·Christopher McGuiganStanley Chamberlain
Nov 22, 2011·Trends in Pharmacological Sciences·Roland SeifertStephen R Sprang
Dec 14, 2011·European Journal of Medicinal Chemistry·Matthäus GetlikDaniel Rauh
Jan 28, 2012·European Journal of Medicinal Chemistry·Ranjith P KaruvalamN Suchetha Kumari
May 15, 2012·Trends in Microbiology·Roland Seifert, Stefan Dove
Jun 8, 2013·Bioorganic & Medicinal Chemistry Letters·Zulan PiPatrick Y S Lam
Sep 6, 2013·The Journal of Pharmacology and Experimental Therapeutics·Cameron S BrandCarmen W Dessauer
Oct 23, 2013·Antimicrobial Agents and Chemotherapy·Markéta ŠmídkováHelena Mertlíková-Kaiserová
Aug 22, 2014·Chemical Reviews·Ugo PradereRaymond F Schinazi
Dec 2, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Val J Watts
Dec 5, 2017·Bioorganic & Medicinal Chemistry Letters·Guan-Sheng JiaoAlan T Johnson
Apr 26, 2020·Current Opinion in Structural Biology·Basavraj KhannpnavarVolodymyr Korkhov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.